Wearable Skin Sensors to Assess Nocturnal Scratch Behavior

Overview

Pilot study of flexible and wearable sensor to monitor nocturnal scratching behavior

Full Title of Study: “A Single Arm, Prospective Clinical Study Using Novel Wearable Sensors to Assess the Improvement of Nocturnal Scratch Behavior and Sleep Quality in Children With Mild-to-moderate Atopic Dermatitis Treated With Topical Crisaborole”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: August 30, 2021

Detailed Description

Present an advanced flexible, and wearable sensor intimately coupled to the skin that can measure the full spectrum of relevant physiological parameters associated with atopic dermatitis including scratch count, scratch duration, scratch intensity, heart rate, heart rate variability and respiratory rate.

Interventions

  • Drug: Crisaborole
    • Subject to apply topical crisaborole twice daily to the affected atopic dermatitis areas
  • Device: Scratch sensor
    • advanced, flexible and wearable skin sensor

Arms, Groups and Cohorts

  • Crisaborole and wearable sensor
    • Subjects will apply topical crisaborole twice daily to the affected atopic dermatitis areas for three weeks.

Clinical Trial Outcome Measures

Primary Measures

  • Percent agreement of scratching between the experimental sensor and the infrared camera
    • Time Frame: 3 weeks

Secondary Measures

  • Improvement of sleep parameters (time asleep) measured by the experimental sensor during treatment
    • Time Frame: 3 weeks
    • Baseline compared to treatment time points will be compared in units of time (minutes/hours)
  • Improvement of sleep parameters (time until onset of sleep) measured by the experimental sensor
    • Time Frame: 3 weeks
    • Baseline compared to treatment time points will be compared in units of time (minutes/hours)
  • Improvement of sleep parameters (heart rate) measured by the experimental sensor
    • Time Frame: 3 weeks
    • Baseline compared to treatment time points will be compared in units of beats/min
  • Improvement of sleep parameters (respiratory rate) measured by the experimental sensor
    • Time Frame: 3 weeks
    • Baseline compared to treatment time points will be compared in units of breaths/min.

Participating in This Clinical Trial

Inclusion Criteria

  • Participants with mild to moderate atopic dermatitis ages 2 years or older. This will be determined by clinical diagnosis of AD according to the Hanifin and Rajka criteria with a baseline Investigators Global Assessment score of mild (2) or moderate (3) – Systemic therapy use (e.g. oral corticosteroid, cyclosporine, methotrexate, phototherapy) within 28 days of subject enrollment – Topical corticosteroid use or topical calcineurin inhibitor use within 14 days of subject enrollment – Willingness and ability to set up an infrared video camera nightly – Willing to apply topical crisaborole twice daily to affected atopic dermatitis areas of the body Exclusion Criteria:

  • Active skin or systemic infection – Inability to operate a smartphone or video camera – Active atopic dermatitis on he dorsum of the hand or suprasternal notch

Gender Eligibility: All

Minimum Age: 2 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Northwestern University
  • Collaborator
    • Pfizer
  • Provider of Information About this Clinical Study
    • Principal Investigator: Shuai (Steve) Xu, Principal Investigator – Northwestern University
  • Overall Official(s)
    • Shuai Xu, Principal Investigator, Northwestern University

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.